Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on immunosuppressive therapy

N G Singer1, W J McCune

  • 1536 RB & C, Division of Pediatric Immunology Allergy and Rheumatology, Cleveland, OH 44106, USA.

Current Opinion in Rheumatology
|June 3, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The devil's in the dosing: severe drug-induced liver injury in a hydroxychloroquine-naive patient with subacute cutaneous lupus erythematosus and porphyria cutanea tarda.

Lupus·2018
Same author

The ratio of erythrocyte sedimentation rate to C-reactive protein is useful in distinguishing infection from flare in systemic lupus erythematosus patients presenting with fever.

Lupus·2018
Same author

Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis.

Clinical and experimental immunology·2017
Same author

Increased usage of special educational services by children born to mothers with systemic lupus erythematosus and antiphospholipid antibodies.

Lupus science & medicine·2014
Same author

Effects of obesity on health-related quality of life in juvenile-onset systemic lupus erythematosus.

Lupus·2014
Same author

In utero azathioprine exposure and increased utilization of special educational services in children born to mothers with systemic lupus erythematosus.

Arthritis care & research·2012
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

This review covers recent advances in immunosuppressive agents for autoimmune and rheumatic diseases. It highlights cyclophosphamide, cyclosporine, and FK506, alongside their associated toxicities.

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Immunosuppressive agents are crucial for managing autoimmune and rheumatic diseases.
  • Recent research has focused on novel applications and toxicities of these drugs.

Purpose of the Study:

  • To review recent literature on immunosuppressive agents.
  • To categorize studies based on drug class and disease indication.
  • To summarize findings on drug toxicity.

Main Methods:

  • Systematic review of selected articles published within the past year.
  • Categorization of studies into three main themes: cyclophosphamide use, newer agents (cyclosporine, FK506), and toxicity.

Main Results:

  • Pulse cyclophosphamide shows utility in autoimmune diseases beyond systemic lupus erythematosus.

Related Experiment Videos

  • Cyclosporine and FK506 are being explored in various rheumatic conditions.
  • Significant attention is given to the toxicity profiles of these immunosuppressive agents.

    • Conclusions:

    • Recent research expands the use of established and novel immunosuppressive agents in rheumatology.
    • Understanding and managing drug toxicity remains a critical aspect of immunosuppressive therapy.